Slika omota

The inhibitory effect of dihydroartemisinin on non-small cells lung cancer

Dihydroartemisinin (DHA) is an artemisinin (ART) derivative used for the treatment of all kinds of malaria, especially for falciparum malaria and dangerous malaria. With the in-depth research, DHA has attracted more attentions in the field of anticancer. We aim to explore the inhibitory effect of DH...

Spremljeno u:

Bibliografski detalji
Glavni autori:	Yan Li (Autor), Guijie Luan (Autor), Ping Guo (Autor)
Format:	Knjiga
Izdano:	Elsevier, 2021-12-01T00:00:00Z.
Teme:	article
Online pristup:	Connect to this object online.
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!

Slični predmeti

Inhibitory Effect of Dihydroartemisinin on the Proliferation and Migration of Melanoma Cells and Experimental Lung Metastasis From Melanoma in Mice
od: Qi Zhang, i dr.
Izdano: (2021)

The coexpression of multi-immune inhibitory receptors on T lymphocytes in primary non-small-cell lung cancer
od: Guo WJ, i dr.
Izdano: (2017)

Systematic Transcriptome Analysis Reveals the Inhibitory Function of Cinnamaldehyde in Non-Small Cell Lung Cancer
od: Ru Chen, i dr.
Izdano: (2021)

Dihydroartemisinin enhances the inhibitory effect of sorafenib on HepG2 cells by inducing ferroptosis and inhibiting energy metabolism
od: Zhao Cui, i dr.
Izdano: (2022)

Inhibitory Effect of Kurarinone on Growth of Human Non-small Cell Lung Cancer: An Experimental Study Both in Vitro and in Vivo Studies
od: Jie Yang, i dr.
Izdano: (2018)

Autophagy-dependent cell cycle arrest in esophageal cancer cells exposed to dihydroartemisinin
od: Qiang Ma, i dr.
Izdano: (2020)

Small molecule purine and pseudopurine derivatives: synthesis, cytostatic evaluations and investigation of growth inhibitory effect in non-small cell lung cancer A549
od: Andrea Bistrović, i dr.
Izdano: (2018)

Current status of immunotherapy for non-small cell lung cancer
od: Tao Yang, i dr.
Izdano: (2022)

Evaluation of the Anticancer Activity of a Bile Acid-Dihydroartemisinin Hybrid Ursodeoxycholic-Dihydroartemisinin in Hepatocellular Carcinoma Cells
od: Tzu-En Huang, i dr.
Izdano: (2020)

Targeting glycolysis in non-small cell lung cancer: Promises and challenges
od: Jia-Qi Xu, i dr.
Izdano: (2022)

Recent progress of small-molecule of RET inhibitors against Non-small cell lung cancer
od: Jiayi Shen, i dr.
Izdano: (2024)

Sintilimab for the treatment of non-small cell lung cancer
od: Lin Zhang, i dr.
Izdano: (2022)

Dihydroartemisinin regulates apoptosis, migration, and invasion of ovarian cancer cells via mediating RECK
od: Jingfei Zheng, i dr.
Izdano: (2021)

Chemoresistance factors in non-small cell lung cancer
od: А. I. Shevchenko, i dr.
Izdano: (2016)

Recent progress in targeted therapy for non-small cell lung cancer
od: Yanxia Xiao, i dr.
Izdano: (2023)

Non-Small-Cell Lung Cancer. Unusual Small Bowel Metastasis with Invagination
od: Miguel Ángel Serra Valdés, i dr.
Izdano: (2017)

Non-Small-Cell Lung Cancer. Unusual Small Bowel Metastasis with Invagination
od: Miguel Ángel Serra Valdés, i dr.
Izdano: (2017)

Addition of metformin for non-small cell lung cancer patients receiving antineoplastic agents
od: Yan Wang, i dr.
Izdano: (2023)

Anticancer effects of myricetin derivatives in non‐small cell lung cancer in vitro and in vivo
od: Mengmeng Li, i dr.
Izdano: (2022)

Effect of fermentation on the constituents in the branches and leaves of Taxus media and non-small cell lung cancer
od: Xing Guo, i dr.
Izdano: (2024)

Design, Synthesis and Anti-Lung Cancer Evaluation of 1, 2, 3-Triazole Tethered Dihydroartemisinin-Isatin Hybrids
od: Haodong Hou, i dr.
Izdano: (2021)

The Role of Prostaglandin-Endoperoxide Synthase-2 in Chemoresistance of Non-Small Cell Lung Cancer
od: Xiao-mian Lin, i dr.
Izdano: (2019)

PHARMACOECONOMIC ASPECTS OF NON-SMALL CELL LUNG CANCER IMMUNOTHERAPY
od: A. V. Rudakova, i dr.
Izdano: (2017)

Iterative surgical resections in non-small cell lung cancer
od: Ahmet Ucvet, i dr.
Izdano: (2022)

Therapeutic Implications of PTEN in Non-Small Cell Lung Cancer
od: Zaid Sirhan, i dr.
Izdano: (2023)

Inhaled Medicines for Targeting Non-Small Cell Lung Cancer
od: Arwa Omar Al Khatib, i dr.
Izdano: (2023)

First line Immunotherapy for Non-Small Cell Lung Cancer
od: Nicola J. Nasser, i dr.
Izdano: (2020)

In vitro Non-Small Cell Lung Cancer Inhibitory Effect by New Diphenylethane Isolated From Stems and Leaves of Dioscorea oppositifolia L. via ERβ-STAT3 Pathway
od: Mengnan Zeng, i dr.
Izdano: (2021)

Therapies Targeting Immune Cells in Tumor Microenvironment for Non-Small Cell Lung Cancer
od: Wei Ye, i dr.
Izdano: (2023)

Identification and therapeutic evaluation of ALK rearrangements in non‐small‐cell lung cancer
od: Ruiying Zhao, i dr.
Izdano: (2022)

Molecular profiling and prognostic biomarkers in chinese non-small cell lung cancer cohort
od: Fangfang Shen, i dr.
Izdano: (2023)

Taraxerone triterpene inhibits cancer cell growth by inducing apoptosis in non-small cell lung cancer cells
od: Xu-Chen Ma, i dr.
Izdano: (2016)

Sugemalimab plus chemotherapy vs. chemotherapy for metastatic non-small-cell lung cancer: A cost-effectiveness analysis
od: Xueyan Liang, i dr.
Izdano: (2023)

Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab
od: Fenge Jiang, i dr.
Izdano: (2022)

Impact of socioeconomic status on cancer staging, survival in non-small cell lung cancer
od: Xianghui Yang, i dr.
Izdano: (2022)

miRNAs in anti-cancer drug resistance of non-small cell lung cancer: Recent advances and future potential
od: Hang Yan, i dr.
Izdano: (2022)

Prediction and validation of common targets in atherosclerosis and non-small cell lung cancer influenced by atorvastatin
od: Yu-qian Li, i dr.
Izdano: (2023)

Guaiazulene Triggers ROS-Induced Apoptosis and Protective Autophagy in Non-small Cell Lung Cancer
od: Qin Ye, i dr.
Izdano: (2021)

Docetaxel-loaded exosomes for targeting non-small cell lung cancer: preparation and evaluation in vitro and in vivo
od: Ying Wang, i dr.
Izdano: (2021)

Effectiveness and safety of atezolizumab, nivolumab and pembrolizumab in metastatic non-small cell lung cancer
od: Amparo Burgos-San José, i dr.
Izdano: (2021)